Exiqon operates in two business areas: Life Sciences and Diagnostics.
Exiqon is a leading supplier of flexible solutions for RNA research. Exiqon's products and services are used by researchers in academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of disease. Taking advantage of our proprietary LNA™ technology, our product lines offer superior specificity and sensitivity for analysis of microRNA, mRNA and long non-coding RNA. Exiqon's products and services encompass the entire workflow from sample preparation to expression analysis (Sequencing, Array and qPCR), detection and functional analysis both in vitro
and in vivo
. Exiqon Services offers expertise in RNA Next Generation Sequencing, microRNA profiling and biomarker discovery from clinical samples.
Exiqon Diagnostics are pioneering the area of microRNA cancer biomarker discovery in liquid biopsies (serum, plasma and urine and other biofluids). Exiqon Diagnostics collaborates with pharmaceutical companies in their effort to develop new medicines based on non-coding and coding RNA as biological markers, and novel molecular diagnostic tests to help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
In June 2016, Exiqon was acquired by QIAGEN
. We are excited to bring Exiqon's unique products and services into the QIAGEN portfolio. The integration of Exiqon and QIAGEN will enable even more researchers to access a comprehensive range of the very best Sample to Insight solutions, and drive the development of new innovative tools for RNA research in the future. We are fully committed to continuing to support your research with the same diligence and focus on your success that you have come to expect from us.
For more information about QIAGEN please visit qiagen.com